Product Information
GRALISE ER 900 MG TABLET is a brand product labeled by Almatica Pharma LLC, priced at $15.2075 per EA under NDC 52427089060. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jan 28, 2011. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
900 mg/1
Manufacturer
Almatica Pharma LLCNDC
52427089060
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
New Drug (NDA)
FDA Application
NDA022544FDA Approved
1/28/2011
TE Code
AB2
On Market Since
12/31/2023
Pharmacological Classes
Price Statistics
The NADAC for GRALISE ER 900 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.2075 per EA |
|---|---|
| All-time high | $15.3483 (Oct 15, 2025) |
| All-time low | $15.1976 (Apr 17, 2024) |
| 52-week high | $15.3483 |
| 52-week low | $15.2075 |
| Median price | $15.3004 |
| Average price | $15.2892 |
| Largest weekly change | -0.3% (Sep 23, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the gabapentin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Almatica Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GRALISE ER 900 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GRALISE ER 900 MG TABLET, manufactured by Almatica Pharma LLC, is $15.2075 per EA (NDC 52427089060), effective Sep 30, 2026.
How has the price of GRALISE ER 900 MG TABLET changed over time?
Over the history we have for it, the NADAC for GRALISE ER 900 MG TABLET has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for GRALISE ER 900 MG TABLET?
Since Apr 17, 2024, the NADAC for GRALISE ER 900 MG TABLET has ranged from a low of $15.1976 (Apr 17, 2024) to a high of $15.3483 (Oct 15, 2025), with a median of $15.3004 per EA.
Are there cheaper alternatives to GRALISE ER 900 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of GRALISE ER 900 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GRALISE ER 900 MG TABLET?
GRALISE ER 900 MG TABLET (NDC 52427089060) is labeled by Almatica Pharma LLC, and CMS classifies it as a brand product.